Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates

Aclaris Therapeutics, Inc.

2025-Q3 EPS reported -$0.37 revenue$6,531,000

Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.
Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.
Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.
Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.
R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.